David Amsellem
Stock Analyst at Piper Sandler
Total Price Targets
40
Stocks Covered
21
Sectors
Healthcare
Most Recent
Dec 10, 2025
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by David Amsellem
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals plc | $219.00 | $202.38 | +8.2% | 3 | Dec 10, 2025 |
| AMGN | Amgen Inc. | $381.00 | $328.69 | +15.9% | 1 | Nov 14, 2025 |
| ABBV | AbbVie Inc. | $289.00 | $206.29 | +40.1% | 1 | Nov 5, 2025 |
| OGN | Organon & Co. | $5.00 | $13.29 | -62.4% | 4 | Oct 27, 2025 |
| ALKS | Alkermes plc | $45.00 | $33.49 | +34.3% | 2 | Oct 23, 2025 |
| ANIP | ANI Pharmaceuticals, Inc. | $94.00 | $80.00 | +17.5% | 1 | Aug 8, 2025 |
| BMY | Bristol-Myers Squibb Company | $65.00 | $58.22 | +11.6% | 1 | Apr 22, 2025 |
| AMPH | Amphastar Pharmaceuticals, Inc. | $32.00 | $21.81 | +46.7% | 4 | Mar 21, 2025 |
| COLL | Collegium Pharmaceutical, Inc. | $36.00 | $34.18 | +5.3% | 3 | Feb 4, 2025 |
| AMRX | Amneal Pharmaceuticals, Inc. | $11.00 | $12.84 | -14.3% | 2 | Nov 11, 2024 |
| PCRX | Pacira BioSciences, Inc. | $12.00 | $24.40 | -50.8% | 2 | Nov 7, 2024 |
| INDV | Indivior Pharmaceuticals Inc | $15.00 | $37.51 | -60.0% | 2 | Oct 11, 2024 |
| SUPN | Supernus Pharmaceuticals, Inc. | $36.00 | $47.99 | -25.0% | 2 | Sep 11, 2024 |
| NBIX | Neurocrine Biosciences, Inc. | $159.00 | $131.64 | +20.8% | 2 | Aug 29, 2024 |
| CORT | Corcept Therapeutics Incorporated | $38.00 | $51.08 | -25.6% | 2 | Jul 30, 2024 |
| AXSM | Axsome Therapeutics, Inc. | $115.00 | $204.09 | -43.7% | 1 | May 28, 2024 |
| IRWD | Ironwood Pharmaceuticals, Inc. | $18.00 | $4.46 | +304.0% | 2 | May 22, 2024 |
| XERS | Xeris Biopharma Holdings, Inc. | $3.00 | $6.26 | -52.1% | 1 | May 10, 2024 |
| BHC | Bausch Health Companies Inc. | $9.00 | $5.67 | +58.7% | 1 | Apr 29, 2024 |
| AQST | Aquestive Therapeutics, Inc. | $10.00 | $4.18 | +138.9% | 1 | Apr 11, 2024 |
| VTRS | Viatris Inc. | $13.00 | $14.98 | -13.2% | 2 | Mar 28, 2024 |
Recent Activity
- Dec 10, 2025— Set$219.00price target onJAZZ(Jazz Pharmaceuticals plc)
- Nov 14, 2025— Set$381.00price target onAMGN(Amgen Inc.)
- Nov 5, 2025— Set$289.00price target onABBV(AbbVie Inc.)
- Oct 27, 2025— Set$5.00price target onOGN(Organon & Co.)
- Oct 23, 2025— Set$45.00price target onALKS(Alkermes plc)
- Aug 8, 2025— Set$94.00price target onANIP(ANI Pharmaceuticals, Inc.)
- May 15, 2025— Set$18.00price target onOGN(Organon & Co.)
- Apr 22, 2025— Set$65.00price target onBMY(Bristol-Myers Squibb Company)
- Mar 21, 2025— Set$32.00price target onAMPH(Amphastar Pharmaceuticals, Inc.)
- Feb 4, 2025— Set$36.00price target onCOLL(Collegium Pharmaceutical, Inc.)
- Dec 5, 2024— Set$37.00price target onALKS(Alkermes plc)
- Nov 11, 2024— Set$11.00price target onAMRX(Amneal Pharmaceuticals, Inc.)
- Nov 7, 2024— Set$12.00price target onPCRX(Pacira BioSciences, Inc.)
- Oct 11, 2024— Set$15.00price target onINDV(Indivior Pharmaceuticals Inc)
- Sep 13, 2024— Set$22.00price target onINDV(Indivior Pharmaceuticals Inc)
- Sep 11, 2024— Set$36.00price target onSUPN(Supernus Pharmaceuticals, Inc.)
- Aug 29, 2024— Set$159.00price target onNBIX(Neurocrine Biosciences, Inc.)
- Aug 9, 2024— Set$37.00price target onCOLL(Collegium Pharmaceutical, Inc.)
- Aug 8, 2024— Set$66.00price target onAMPH(Amphastar Pharmaceuticals, Inc.)
- Jul 30, 2024— Set$38.00price target onCORT(Corcept Therapeutics Incorporated)
Frequently Asked Questions
Who is David Amsellem?
David Amsellem is a stock analyst at Piper Sandler covering 21 stocks primarily in Healthcare. They have issued 40 price targets since Mar 12, 2022.
What stocks does David Amsellem cover?
David Amsellem currently covers 21 stocks, including OGN, AMPH, JAZZ, COLL, ALKS.
What is David Amsellem's latest price target?
David Amsellem's most recent price target was $219.00 on JAZZ (Jazz Pharmaceuticals plc), set on Dec 10, 2025.
What is David Amsellem's highest price target?
David Amsellem's highest issued price target is $381.00 on AMGN, set on Nov 14, 2025.
More Analysts at Piper Sandler
Coverage based on publicly published price targets. Not investment advice.